ONCOFID-P-B (Paclitaxel-Hyaluronic Acid) In The Intravesical Therapy Of Patients With Non-Muscle Invasive Cancer Of The Bladder. A Phase II Marker Lesion Study.
Phase of Trial: Phase II
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Paclitaxel-hyaluronic acid conjugate (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Fidia Farmaceutici
- 20 Mar 2018 Status changed from recruiting to completed, as per the results presented at the 33rd Congress of the European Association of Urology
- 18 Mar 2018 According to a Fidia Farmaceutici media release, positive results were presented at the Italian Pharmaceutical R&D Excellence at the 33rd Congress of the European Association of Urology.
- 18 Mar 2018 Results presented in a Fidia Farmaceutici media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History